Global Clostridium Difficile Treatment Market 2017-2021 - Product Image

Global Clostridium Difficile Treatment Market 2017-2021

  • ID: 4319123
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Actelion Pharmaceuticals
  • Da Volterra
  • MGB Biopharma
  • Pfizer
  • Sanofi Pasteur
  • Summit Therapeutics
  • MORE

About Clostridium Defficile Treatment

CDI is a bacterium that can cause symptoms such as diarrhea and life-threatening inflammation of the colon. CDI mostly affects elderly people who frequent hospitals or people who live in long-term care facilities. CDI can also occur due to the prolonged use of antibiotics. The first line of treatment for CDI is antibiotics.

The analysts forecast the global clostridium defficile treatment market to grow at a CAGR of 5.14% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global clostridium defficile treatment market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

The report, Global Clostridium Defficile Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors

  • Actelion Pharmaceuticals
  • Merck
  • Pfizer
  • Summit Therapeutics

Other prominent vendors

  • Astellas Pharma
  • CRESTOVO
  • Da Volterra
  • Immuron
  • MGB Biopharma
  • Novartis
  • Otsuka Pharmaceutical
  • Rebiotix
  • Romark Laboratories
  • Sanofi Pasteur
  • Seres Therapeutics
  • Shire
  • Synthetic Biologics
  • Valeant Pharmaceuticals
  • Valneva

Market drivers

  • Rise in aging population
  • For a full, detailed list, view the full report

Market challenges

  • High cost of therapy and high mortality rate
  • For a full, detailed list, view the full report

Market trends

  • Special designation
  • For a full, detailed list, view the full report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Actelion Pharmaceuticals
  • Da Volterra
  • MGB Biopharma
  • Pfizer
  • Sanofi Pasteur
  • Summit Therapeutics
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Overview
PART 05: Pipeline landscape

PART 06: Market landscape
  • Overview
  • Market size and forecast
  • Five forces analysis
PART 07: Market segmentation by drug category
  • Narrow spectrum antibiotic
  • Broad spectrum antibiotics
PART 08: Geographical segmentation
  • Americas
  • EMEA
  • APAC
PART 09: Decision framework

PART 10: Drivers and challenges
  • Market drivers
  • Market challenges
PART 11: Market trends
  • Emergence of vaccines
  • Special designation
  • Drug candidates with strong MOA
PART 12: Vendor landscape
  • Competitive scenario
PART 13: Key vendor analysis
  • Actelion Pharmaceuticals
  • Merck
  • Pfizer
  • Summit Therapeutics
  • Other prominent vendors
PART 14: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: CDI: Symptoms
Exhibit 02: Various causes of CDI
Exhibit 03: Global CDI treatment market: Key pipeline molecules by vendors 2016
Exhibit 04: Key clinical trials
Exhibit 05: Global CDI treatment market: Overview
Exhibit 06: Global CDI treatment market 2016-2021 ($ million)
Exhibit 07: Five forces analysis
Exhibit 08: Global CDI treatment market: Segmentation by drug category 2016
Exhibit 09: Global CDI narrow spectrum antibiotics market 2016-2021 ($ million)
Exhibit 10: Global CDI broad spectrum antibiotics market 2016-2021 ($ million)
Exhibit 11: Global CDI treatment market: Segmentation by geography 2016 and 2021 (% share)
Exhibit 12: Global CDI treatment market: Revenue by geography 2016-2021 ($ million)
Exhibit 13: Americas: Overview
Exhibit 14: CDI treatment market in Americas 2016-2021 ($ million)
Exhibit 15: EMEA: Overview
Exhibit 16: CDI treatment market in EMEA 2016-2021 ($ million)
Exhibit 17: APAC: Overview
Exhibit 18: CDI treatment market in APAC 2016-2021 ($ million)
Exhibit 19: Drugs under development
Exhibit 20: Vaccines in development stage
Exhibit 21: Companies that have benefited from special designations
Exhibit 22: Global CDI treatment market: Competitive structure analysis 2016
Exhibit 23: Global CDI treatment market: Strategic success factors of companies
Exhibit 24: Actelion: Key highlights
Exhibit 25: Actelion: Strength assessment
Exhibit 26: Actelion: Strategy assessment
Exhibit 27: Actelion: Opportunity assessment
Exhibit 28: Merck: Key highlights
Exhibit 29: Merck: Strength assessment
Exhibit 30: Merck: Strategy assessment
Exhibit 31: Merck: Opportunity assessment
Exhibit 32: Pfizer: Key highlights
Exhibit 33: Pfizer: Strength assessment
Exhibit 34: Pfizer: Strategy assessment
Exhibit 35: Pfizer: Opportunity assessment
Exhibit 36: Summit Therapeutics: Key highlights
Exhibit 37: Summit Therapeutics: Strength assessment
Exhibit 38: Summit Therapeutics: Strategy assessment
Exhibit 39: Summit Therapeutics: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Actelion Pharmaceuticals
  • Da Volterra
  • MGB Biopharma
  • Pfizer
  • Sanofi Pasteur
  • Summit Therapeutics
  • MORE
New Report Released: – Global Clostridium Defficile Treatment Market 2017-2021

The author of the report recognizes the following companies as the key players in the global clostridium defficile treatment market: Actelion Pharmaceuticals, Merck, Pfizer, and Summit Therapeutics.

Other Prominent Vendors in the market are: Astellas Pharma, CRESTOVO, Da Volterra, Immuron, MGB Biopharma, Novartis, Otsuka Pharmaceutical, Rebiotix, Romark Laboratories, Sanofi Pasteur, Seres Therapeutics, Shire, Synthetic Biologics, Valeant Pharmaceuticals, and Valneva.

Commenting on the report, an analyst from the research team said: “One trend in the market is special designation. Special designations such as Fast Track and Qualified Infectious Disease Product (QIDP), which are provided by the FDA, will encourage vendors to launch new products. These designations are beneficial for the market as they will enable the quick completion of the clinical trial process.”

According to the report, one driver in the market is rise in aging population. As people age, their immune systems deteriorate. People above the age of 60 may experience several medical complications. Aging plays a significant role in the manifestation of CDI. Research studies estimate that people above the age of 60 are susceptible to CDI, with the median age of diagnosis being 70. The rise in the aging population will increase the number of people affected by CDI.

Further, the report states that one challenge in the market is high cost of therapy and high mortality rate. CDI requires constant monitoring and medication, which leads to the increased use of antibiotics. Considering these antibiotics are expensive and have several side effects, patients end up discontinuing treatment. This leads to reduced patient adherence and shrinking the market value. The morbidity, mortality, and medical care costs of CDI have been growing.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Actelion Pharmaceuticals
  • Astellas Pharma
  • CRESTOVO
  • Da Volterra
  • Immuron
  • Merck
  • MGB Biopharma
  • Novartis
  • Otsuka Pharmaceutical
  • Pfizer
  • Rebiotix
  • Romark Laboratories
  • Sanofi Pasteur
  • Seres Therapeutics
  • Shire
  • Summit Therapeutics
  • Synthetic Biologics
  • Valeant Pharmaceuticals
  • Valneva
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll